Table 2 Neoadjuvant therapy adverse events
Grade (CTCAE v 4.0) | Conventional group (n = 101) |  | Combined group (n = 102) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Grade 1–2 | Grade 3 | Grade 4 | ≥Grade 3 | Grade 1–2 | Grade 3 | Grade 4 | ≥Grade 3 | ||
All adverse events | 60 (59.4%) | 16 (15.8%) | 3 (3%) | 17 (16.8%) * | Â | 66 (64.7%) | 25 (24.5%) | 5 (4.9%) | 26(25.5%) * |
Leukopenia | 26 (25.7%) | 1 (1%) | 1 (1%) | 2 (2%) | 25 (24.5%) | 4 (3.9%) | 4 (3.9%) | 8 (7.8%) | |
Neutropenia | 31 (30.7%) | 3 (3%) | 1 (1%) | 4 (4%) | 22 (21.6%) | 8 (7.8%) | 4 (3.9%) | 12 (11.8%) | |
Thrombocytopenia | 7 (6.9%) | 1 (1%) | 0 | 1 (1%) | 7 (6.86%) | 2 (2%) | 0 | 2 (2%) | |
Febrile neutropenia | 0 | 2 (2%) | 0 | 2 (2%) | 0 | 2 (2%) | 1 (1%) | 3 (2.9%) | |
Anemia | 13 (12.9%) | 9 (8.9%) | 0 | 9 (8.9%) | 19 (18.6%) | 6 (7.8%) | 1 (1%) | 7 (6.86%) | |
Nausea and vomiting | 16 (15.8%) | 4 (4%) | 0 | 4 (4%) | 29 (28.4%) | 3 (2.9%) | 0 | 3 (2.9%) | |
Anorexia | 11 (10.9%) | 0 | 0 | 0 | 19 (18.6%) | 1 (1%) | 0 | 1 (1%) | |
ALT or AST increased | 18 (17.8%) | 2 (2%) | 0 | 2 (2%) | 13 (12.7%) | 5 (4.9%) | 0 | 5 (4.9%) | |
Serum creatinine increased | 3 (3%) | 0 | 0 | 0 | 1 (1%) | 0 | 0 | 0 | |
Infection | 1 (1%) | 0 | 0 | 0 | 0 | 3 (2.9%) | 0 | 3 (2.9%) | |
Diarrhea | 3 (3%) | 3 (3%) | 0 | 3 (3%) | 1 (1%) | 0 | 0 | 0 | |
Other | 2 (2%) | 0 | 1 (1%) | 1 (1%) | 2 (2%) | 2 (2%) | 0 | 2 (2%) | |